The ex vivo stimulation of NK cells with IL-12, IL-15, and IL-18 to generate CIML NK cells has demonstrated superior anti-tumour efficacy in preclinical studies [34] and CIML NK cells are now under assessment in multiple clinical trials for both solid and haematological malignancies (Table 1). The gene discussed is IL15; the disease is neoplasm.